Australian firm Clinuvel Pharmaceuticals Ltd. has announced the first commercial launch in Europe of its orphan drug Scenesse (afamelanotide) for the rare genetic disorder erythropoietic protoporphyria (EPP).
Patients in the Netherlands are this week beginning treatment with Scenesse, which received EU approval in 2014 for the prevention...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
